Literature DB >> 25902028

Effect of combined treatment with cyclophosphamidum and allicin on neuroblastoma-bearing mice.

Xiang-Yang Gao1, Xian-Jie Geng1, Wen-Long Zhai2, Xian-Wei Zhang1, Yuan Wei1, Guang-Jun Hou3.   

Abstract

OBJECTIVE: To evaluate the efficacy of allicin combined with cyclophosphamide on neuroblastoma (NB)-bearing mice and explore the immunological mechanism in it.
METHODS: A total of 30 NB-bearing mice were equally randomized into model group, cyclophosphamide group and combined therapy group, 10 nudemice were set as normal saline (NS) group. Cyclophosphamide group and combined therapy group were weekly injected with 60 mg/kg cyclophosphamide for four weeks; besides, combined therapy group was given with allicin (10 mg/kg/d) by gastric perfusion for 4 weeks; model group and NS group were given with the same volume of NS. Serum VEGF content was detected by ELISA pre-treating (0 d) and on the 3rd d, 14th d and 28th d; on 29th d, all mice were sacrificed and the tumor, liver, spleen and thymic tissues were weighted. Tumors were made into paraffin section for detecting tumor cell apoptosis and proliferation by TUNEL and BrdU method, respectively. Survival curves were drawn by Kaplan-Meier method.
RESULTS: After treatment, both treatment groups relieved on viscera indexes, VEGF level, T cell subsets distribution and tumor growth and each index of combined therapy group was better than cyclophosphamide group (P<0.05 or 0.01); only combined therapy group could significantly increase the lifetime of NB-bearing mice (μ (2)=5.667, P=0.017).
CONCLUSIONS: Allicin can improve T cell subsets distribution and inhibit VEGF expression through its immunomodulatory activity, thereby improve the efficiency on NB in coordination with cyclophosphamide.
Copyright © 2015 Hainan Medical College. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allicin; Cyclophosphamide; NB–bearing mice; Neuroblastoma; T cell subsets

Year:  2015        PMID: 25902028     DOI: 10.1016/S1995-7645(14)60304-7

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  4 in total

1.  Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.

Authors:  Chad R Schultz; Martin C H Gruhlke; Alan J Slusarenko; André S Bachmann
Journal:  J Nat Prod       Date:  2020-08-12       Impact factor: 4.803

2.  Phytochemical Analysis and In Vitro Effects of Allium fistulosum L. and Allium sativum L. Extracts on Human Normal and Tumor Cell Lines: A Comparative Study.

Authors:  Adrian Bogdan Țigu; Cristian Silviu Moldovan; Vlad-Alexandru Toma; Anca Daniela Farcaș; Augustin Cătălin Moț; Ancuța Jurj; Eva Fischer-Fodor; Cristina Mircea; Marcel Pârvu
Journal:  Molecules       Date:  2021-01-22       Impact factor: 4.411

Review 3.  A Review of Medicinal Plants of the Himalayas with Anti-Proliferative Activity for the Treatment of Various Cancers.

Authors:  Hailemeleak Regassa; Anuradha Sourirajan; Vikas Kumar; Sadanand Pandey; Deepak Kumar; Kamal Dev
Journal:  Cancers (Basel)       Date:  2022-08-12       Impact factor: 6.575

Review 4.  Antitumor Effects of Natural Compounds Derived from Allium sativum on Neuroblastoma: An Overview.

Authors:  Carlos César Patiño-Morales; Ricardo Jaime-Cruz; Concepción Sánchez-Gómez; Juan Carlos Corona; Estefani Yaquelin Hernández-Cruz; Ivia Kalinova-Jelezova; José Pedraza-Chaverri; Perla D Maldonado; Carlos Alfredo Silva-Islas; Marcela Salazar-García
Journal:  Antioxidants (Basel)       Date:  2021-12-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.